K-Ras mutations are changing practice in advanced colorectal cancer.
McNeil
Caroline
C
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism*; D000068818:Cetuximab; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D004348:Drug Labeling; D066246:ErbB Receptors / Q000187:drug effects* / Q000378:metabolism; D011905:Genes, ras; D006801:Humans; D009154:Mutation; D000077544:Panitumumab; D015203:Reproducibility of Results
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D000077544:Panitumumab; D066246:ErbB Receptors; D000068818:Cetuximab